UK-based Trimtech Therapeutics has closed an additional USD 14 million in seed funding, bringing its total seed round to USD 47 million (GBP 35 million), to advance its TRIM21-based targeted protein degradation platforms for neurodegenerative diseases. The financing will support the firm's application of proprietary TRIMTAC and TRIMGLUE platforms.
The extension was co-led by Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and BGF, who join an existing syndicate that includes Cambridge Innovation Capital, DDF, M Ventures, Pfizer Ventures, Eli Lilly and Company, MP Healthcare Venture Management, and Cambridge Enterprise Ventures. The company said proceeds will support continued progression of its proprietary platforms and differentiated portfolio. Representatives from JJDC and BGF will join TRIMTECH's board as non-executive directors. No prior funding rounds or previous Trimtech-specific deal history were identified in publicly available sources beyond this seed financing.
Trimtech was founded on academic research into TRIM21, a novel E3 ubiquitin ligase. TRIM21 is distinct from the E3 ligases most commonly exploited in targeted protein degradation, such as cereblon and VHL. The protein functions as an intracellular antibody receptor that normally helps cells recognize and eliminate antibody-bound pathogens. Trimtech's platform seeks to harness this endogenous clearance machinery to selectively target disease-associated protein aggregates, potentially expanding targeted protein degradation beyond the soluble intracellular proteins that have been the primary focus of first-generation degrader technologies.
The company's TRIMTAC platform enables development of heterobifunctional (PROTAC-like) small molecules, while TRIMGLUE enables molecular glue degraders. Resulting molecules are expected to selectively degrade toxic protein aggregates and oligomers associated with neurodegeneration while preserving functional monomeric forms of those same proteins, albeit no development candidates have been detailed publicly to date.